Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 200

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis

Open access
Umemura, Shigeki, Mimaki, Sachiyo, Makinoshima, Hideki, Tada, Satoshi, Ishii, Genichiro, Ohmatsu, Hironobu, Niho, Seiji, Yoh, Kiyotaka, Matsumoto, Shingo, Takahashi, Akiko, Morise, Masahiro, Nakamura, Yuka, Ochiai, Atsushi, Nagai, Kanji, Iwakawa, Reika, Kohno, Takashi, Yokota, Jun, Ohe, Yuichiro, Esumi, Hiroyasu, Tsuchihara, Katsuya, Goto, Koichi · 2014 · Journal of Thoracic Oncology

Abstract

INTRODUCTION: The information regarding therapeutically relevant genomic alterations in small cell lung cancer (SCLC) is not well developed. We analyzed the SCLC genome using an integrative approach to stratify the targetable alterations. METHODS: We performed whole exon sequencing (n = 51) and copy number analysis (n =47) on surgically resected tumors and matched normal tissue samples from treatment-naive Japanese SCLC patients. RESULTS: The demographics of the 51 patients included in this study were as follows: median age, 67 years (range, 42-86 years); female, 9 (18%); history of smoking, 50 (98%); and pathological stage I/II/III/IV, 28/13/9/1, respectively. The average number of nonsynonymous mutations was 209 (range, 41-639; standard deviation, 130). We repeatedly confirmed the high prevalence of inactivating mutations in TP53 and RB1, and the amplification of MYC family members. In addition, genetic alterations in the PI3K/AKT/mTOR pathway were detected in 36% of the tumors: PIK3CA, 6%; PTEN, 4%; AKT2, 9%; AKT3, 4%; RICTOR, 9%; and mTOR, 4%. Furthermore, the individual changes in this pathway were mutually exclusive. Importantly, the SCLC cells harboring active PIK3CA mutations were potentially targetable with currently available PI3K inhibitors. CONCLUSIONS: The PI3K/AKT/mTOR pathway is distinguishable in SCLC genomic alterations. Therefore, a sequencing-based comprehensive analysis could stratify SCLC patients by potential therapeutic targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0000000000000250

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 200

Metadata

Authors
Umemura, S., Mimaki, S., Makinoshima, H., Tada, S., Ishii, G., Ohmatsu, H., Niho, S., Yoh, K., Matsumoto, S., Takahashi, A., Morise, M., Nakamura, Y., Ochiai, A., Nagai, K., Iwakawa, R., Kohno, T., Yokota, J., Ohe, Y., Esumi, H., Tsuchihara, K., & Goto, K.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2014-09
Volume
9
Issue
9
Pages
1324-1331
ISSN
1556-0864 (ISSN-L)
OpenAlex
W1997232290
Cited by
200
References
3
FWCI
6.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis. https://app.cochat.ai/papers/10.1097/jto.0000000000000250
The paper
Umemura, S., Mimaki, S., Makinoshima, H., Tada, S., Ishii, G., Ohmatsu, H., Niho, S., Yoh, K., Matsumoto, S., Takahashi, A., Morise, M., Nakamura, Y., Ochiai, A., Nagai, K., Iwakawa, R., Kohno, T., Yokota, J., Ohe, Y., Esumi, H., . . . Goto, K. (2014). Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0000000000000250

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.